Clinical Trial Update: A Multi-Center Study Evaluating the Safety of AC-170 0.24% [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety of AC-170 0.24% in atopic disease including allergic conjunctivitis has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Atopic Dermatitis
• Atopic Disease

Drugs mentioned

• AC-170 0.24% (AC-170)

Snippet

Sponsor: Aciex Therapeutics, Inc. | Conditions: Atopic Disease (Including Allergic Conjunctivitis) | Phase 3 | Status: COMPLETED | Results posted: 2017-07-26